There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...

Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...

On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...